-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec today, AstraZeneca announced the latest results of its long-acting new coronavirus neutralizing antibody AZD7442 in two phase 3 clinical trials for the prevention and treatment of COVID-19
.
The test results show that a single intramuscular injection of AZD7442 reduces the risk of developing symptomatic COVID-19 by 83% when the follow-up time is 6 months
.
The press release pointed out that 2% of the world’s population may not respond well to the new crown vaccine for a variety of reasons (such as blood cancer patients receiving chemotherapy, patients receiving dialysis, multiple sclerosis or rheumatoid arthritis taking immunosuppressive drugs) Patients, etc.
), this result shows that long-acting neutralizing antibodies may provide them with long-term protection and provide a new option for controlling the epidemic
.
AZD7442 is a long-acting neutralizing antibody combination therapy jointly developed by AstraZeneca and Vanderbilt University Medical Center.
It consists of two neutralizing antibodies that bind to different epitopes of the new coronavirus spike protein
.
AstraZeneca has optimized the antibodies to extend their half-life to three times that of ordinary monoclonal antibodies.
The goal is to provide up to 12 months of protection after a single injection
.
AstraZeneca has submitted an application to the US FDA to seek emergency use authorization to use AZD7442 to prevent or treat COVID-19
.
Image source: WuXi AppTec's content team mapping.
This randomized, double-blind, placebo-controlled phase 3 clinical trial focuses on recruiting high-risk and immunocompromised volunteers.
More than 75% of participants have comorbidities at baseline.
And it includes people who may have a reduced immune response to the vaccine due to a weakened immune system
.
At a median follow-up time of 6 months, a single injection of AZD7442 compared with placebo reduced the volunteer's risk of developing symptomatic COVID-19 by 83%
.
In addition, in the AZD7442 group, no one experienced severe illness or death
.
In the control group, there were 5 critically ill patients and two COVID-19-related deaths
.
In addition, in another phase 3 clinical trial for the treatment of patients with mild to moderate COVID-19, AZD7442, if used within 3 days of the onset of symptoms, can reduce the patient's risk of aggravation or death by 88%
.
The main researcher of AZD7442, Professor Hugh Montgomery of University College London, UK, said: "These results give us confidence and show that long-acting antibody combination therapy can provide long-term protection for vulnerable people and help them return to normal life
.
" At present, there are many biomedicines.
The company's neutralizing antibody therapy has been approved by regulatory agencies around the world or authorized for emergency use.
They cannot replace the new crown vaccine, but together with the new crown vaccine, small molecule antiviral drugs and other new crown therapies, they provide people with more diverse anti-epidemics.
Means
.
Reference materials: [1] New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention.
Retrieved November 18, 2021, from https:// astraz/media-centre/press-releases/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long- term-prevention.
html[2] BIO COVID-19 Therapeutic Development Tracker.
Retrieved November 14, 2021, from https:// disclaimer : WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
.
The test results show that a single intramuscular injection of AZD7442 reduces the risk of developing symptomatic COVID-19 by 83% when the follow-up time is 6 months
.
The press release pointed out that 2% of the world’s population may not respond well to the new crown vaccine for a variety of reasons (such as blood cancer patients receiving chemotherapy, patients receiving dialysis, multiple sclerosis or rheumatoid arthritis taking immunosuppressive drugs) Patients, etc.
), this result shows that long-acting neutralizing antibodies may provide them with long-term protection and provide a new option for controlling the epidemic
.
AZD7442 is a long-acting neutralizing antibody combination therapy jointly developed by AstraZeneca and Vanderbilt University Medical Center.
It consists of two neutralizing antibodies that bind to different epitopes of the new coronavirus spike protein
.
AstraZeneca has optimized the antibodies to extend their half-life to three times that of ordinary monoclonal antibodies.
The goal is to provide up to 12 months of protection after a single injection
.
AstraZeneca has submitted an application to the US FDA to seek emergency use authorization to use AZD7442 to prevent or treat COVID-19
.
Image source: WuXi AppTec's content team mapping.
This randomized, double-blind, placebo-controlled phase 3 clinical trial focuses on recruiting high-risk and immunocompromised volunteers.
More than 75% of participants have comorbidities at baseline.
And it includes people who may have a reduced immune response to the vaccine due to a weakened immune system
.
At a median follow-up time of 6 months, a single injection of AZD7442 compared with placebo reduced the volunteer's risk of developing symptomatic COVID-19 by 83%
.
In addition, in the AZD7442 group, no one experienced severe illness or death
.
In the control group, there were 5 critically ill patients and two COVID-19-related deaths
.
In addition, in another phase 3 clinical trial for the treatment of patients with mild to moderate COVID-19, AZD7442, if used within 3 days of the onset of symptoms, can reduce the patient's risk of aggravation or death by 88%
.
The main researcher of AZD7442, Professor Hugh Montgomery of University College London, UK, said: "These results give us confidence and show that long-acting antibody combination therapy can provide long-term protection for vulnerable people and help them return to normal life
.
" At present, there are many biomedicines.
The company's neutralizing antibody therapy has been approved by regulatory agencies around the world or authorized for emergency use.
They cannot replace the new crown vaccine, but together with the new crown vaccine, small molecule antiviral drugs and other new crown therapies, they provide people with more diverse anti-epidemics.
Means
.
Reference materials: [1] New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention.
Retrieved November 18, 2021, from https:// astraz/media-centre/press-releases/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long- term-prevention.
html[2] BIO COVID-19 Therapeutic Development Tracker.
Retrieved November 14, 2021, from https:// disclaimer : WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment recommendation either
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
.
